Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2017

View Archived Issues

Fluvoxamine maleate approved in Japan for pediatric obsessive-compulsive disorder

Taivex initiates phase I study of T-1101 in advanced refractory solid tumors

Spinraza approved in Japan and Canada

Kyowa Hakko Kirin initiates phase III trial of mogamulizumab in HTLV-1 associated myelopathy

Evidence of activity seen with BGB-A317 in hepatocellular carcinoma

FDA accepts for review resubmission of SUN-101/eFlow NDA

PET using [18F]CTT-1057 effectively images prostate cancer

VenatoRx Pharmaceuticals describes novel beta-lactamase inhibitors

Pfizer divulges new GABA(A) receptor modulators

Rice University patents CJ-16264 analogues

Bayer Pharma describes new potassium channel subfamily K member 3/9 blockers

Novel complement factor D inhibitors discovered at Lifesci Pharmaceuticals

New hBUB1 inhibitors synthesized at Bayer Pharma

Onxeo reports preclinical proof-of-concept results for intravenous AsiDNA

TIM-3 and Gal-9 found to impact disease outcome in myelodysplastic syndromes

Saniona acquires NeuroSearch's remaining interest on acquired assets

M Pharmaceutical adds potential pediatric orphan drug to pipeline

New phase II trial explores use of filgotinib in noninfectious uveitis

Amenalief approved in Japan to treat herpes zoster

Zydus initiates phase II trial of ZYAN-1 to treat anemia in chronic kidney disease

Daiichi Sankyo discontinues Japanese development of etanercept biosimilar CHS-0214

Human adipose-derived stromal cells effectively treat experimental glomerulonephritis

Lytix advances phase I trial of LTX-315

Updated phase I/II data for KTE-C19 in pediatric relapsed/refractory acute lymphoblastic leukemia

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...